Agios reported record third-quarter revenue of $55.4 million, more than four times last year's third quarter. The FDA extended the sickle cell review to February 1st, 2027, while the company held $907 million in cash, cash equivalents and marketable securities.
AGIO · Agios Pharmaceuticals, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Agios reported nine-month revenue growth of $86.8 million, driven by AQVESME and PYRUKYND. The FDA’s mitapivat sickle-cell goal date was extended to February 1, 2027, while nine-month net loss was $264.9 million.
Agios Pharmaceuticals reported third-quarter 2026 mitapivat net revenue of $55.4 million, more than four times $12.9 million. FDA extended the sickle cell disease sNDA goal date to February 1, 2027; cash was $907.0 million at September 30, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Mitapivat revenue grew more than fourfold, AQVESME demand broadened, and new mitapivat and AG-236 data advanced the pipeline; the company held $907.0 million and targets non-GAAP profitability in 2028. Key negatives were the sickle-cell PDUFA delay and REMS information request, along with continuing net loss, higher SG&A, lower cash, and rising cost of sales.
- + Mitapivat net revenue grew to $55.4 million, more than fourfold year over year.
- + AQVESME demand broadened across patient segments, with 619 cumulative completed start forms.
- + The company held $907.0 million in liquidity and targets non-GAAP profitability in 2028.
- + R&D headcount will fall by more than 35%, with associated savings expected in 2027.
- + Mitapivat showed durable hemoglobin improvement and potential kidney and cardiac benefits in sickle cell disease.
- + AG-236 Phase 1 data supported potential every-six-month dosing in polycythemia vera.
- − The FDA extended the mitapivat sickle cell PDUFA goal date by three months to February 1, 2027.
- − The FDA requested additional information to assess whether a REMS is required for sickle cell disease.
- − Net loss remained $65.0 million in the third quarter.
- − SG&A expense increased to $56.5 million from $41.3 million, reflecting launch investment.
- − Cash, cash equivalents, and marketable securities declined to $907.0 million from $1.2 billion.
- − Cost of sales increased to $2.5 million from $1.7 million in the prior-year quarter.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Additional cumulative prescriptions with ASFs in process | 48 | as of September 30, 2026 | — |
| AQVESME patients remaining on therapy after six months | 75% | after six months of treatment | — |
| Cumulative AQVESME prescriptions with completed start forms from REMS-certified physicians | 619 | as of September 30, 2026 | — |
| worldwide net revenues of mitapivat (PYRUKYND and AQVESME) | $55.39M | FY2026 Q3 | +330.0% |
|
|
|||
| cumulative AQVESME prescriptions for thalassemia written by REMS-certified U.S. physicians | 442 | as of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AGIO
this stock
Agios Pharmaceuticals, Inc.
|
$1.78B | +9.0% | -38.5% | — | 10.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 21
Agios reported nine-month revenue growth of $86.8 million, driven by AQVESME and PYRUKYND. The FDA’s mitapivat sickle-cell goal date was extended to February 1, 2027, while nine-month net loss was $264.9 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AGIO | -9.6% | -20.2% | +1.0% | -2.9% | +9.0% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -5.7% | -14.6% | +4.4% | +0.5% | +2.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.